CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro
- PMID: 23313737
- DOI: 10.1016/j.ygyno.2012.12.044
CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro
Abstract
Objective: ErbB4 is a member of the ErbB subfamily of receptor tyrosine kinases with a poorly understood biological role in ovarian cancer. Here, we have addressed the expression, subcellular localization, and prognostic relevance of ErbB4 and its alternatively spliced isoforms in serous ovarian adenocarcinoma.
Methods: A tissue microarray including 482 samples was analyzed by immunohistochemistry, and a series of 198 samples by isoform-specific real-time RT-PCR. The data were statistically analyzed for associations with clinicopathological markers and survival. The functional effect of expressing the relevant ErbB4 isoforms in ovarian cancer cells was addressed by measuring colony formation in soft agar.
Results: While ErbB4 immunoreactivity was present in 90% of the samples, total ErbB4 protein expression was not significantly associated with prognostic markers. However, real-time RT-PCR analysis of serous ovarian cancer samples indicated the presence of two alternatively spliced cytoplasmic isoforms of ERBB4, CYT-1 and CYT-2, previously demonstrated to mediate significantly different cellular activities. Expression of CYT-1, but not of CYT-2, was significantly associated with tumor grade (P=0.014) and poor overall survival (P=0.0028). CYT-1 expression was also an independent prognostic factor (P=0.021) in multivariate analysis of survival. Consistent with a biological effect specific for the one isoform, overexpression of ErbB4 CYT-1, but not of ErbB4 CYT-2, increased anchorage-independent growth of ovarian adenocarcinoma cells in vitro.
Conclusions: These results suggest that expression of a specific ErbB4 isoform, CYT-1, is associated with poor survival and enhanced growth in serous ovarian cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.Hum Pathol. 2013 Aug;44(8):1465-71. doi: 10.1016/j.humpath.2012.12.016. Epub 2013 Mar 1. Hum Pathol. 2013. PMID: 23465277
-
Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.Cancer Res. 2001 Mar 1;61(5):2169-76. Cancer Res. 2001. PMID: 11280782
-
The potential prognostic value of cathepsin D protein in serous ovarian cancer.Arch Gynecol Obstet. 2012 Aug;286(2):465-71. doi: 10.1007/s00404-012-2318-2. Epub 2012 Apr 3. Arch Gynecol Obstet. 2012. PMID: 22476353
-
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.Cancer Res. 2005 Feb 15;65(4):1384-93. doi: 10.1158/0008-5472.CAN-04-3150. Cancer Res. 2005. PMID: 15735025
-
Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma.Gynecol Oncol. 2012 Feb;124(2):311-8. doi: 10.1016/j.ygyno.2011.10.026. Epub 2011 Oct 29. Gynecol Oncol. 2012. PMID: 22044687
Cited by
-
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.Cancer Res Commun. 2022 Jan 7;2(1):10-27. doi: 10.1158/2767-9764.CRC-21-0021. eCollection 2022 Jan. Cancer Res Commun. 2022. PMID: 36860695 Free PMC article.
-
Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.Am J Cancer Res. 2014 Jan 15;4(1):61-72. eCollection 2014. Am J Cancer Res. 2014. PMID: 24482739 Free PMC article.
-
HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer.Oncol Lett. 2018 May;15(5):6629-6635. doi: 10.3892/ol.2018.8124. Epub 2018 Feb 27. Oncol Lett. 2018. PMID: 29616125 Free PMC article.
-
Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors.Explor Target Antitumor Ther. 2021;2(2):187-203. doi: 10.37349/etat.2021.00040. Epub 2021 Apr 30. Explor Target Antitumor Ther. 2021. PMID: 36046141 Free PMC article.
-
Targeting HER (ERBB) signaling in head and neck cancer: An essential update.Mol Aspects Med. 2015 Nov;45:74-86. doi: 10.1016/j.mam.2015.07.001. Epub 2015 Jul 7. Mol Aspects Med. 2015. PMID: 26163475 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous